Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002949 · ClinicalTrials.gov registry record · Phase 1
Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00002949 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 33 participants.
The verdict
NCT00002949, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with vinorelbine and paclitaxel plus radiation therapy in treating patients with advanced cancer arising in the pelvis.
Interventions
- DRUG paclitaxel
- RADIATION radiation therapy
- DRUG vinorelbine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 1996-07 |
| Est. Completion | 2001-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002949
The ClinicalTrials.gov registry entry for NCT00002949 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00002949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002949 about?
NCT00002949 is a clinical study titled "Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with vinorelbine and paclitaxel plu...
What is the current status of trial NCT00002949?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 1996-07. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00002949?
The interventions under investigation include: paclitaxel (DRUG), radiation therapy (RADIATION), vinorelbine tartrate (DRUG).
Who is sponsoring clinical trial NCT00002949?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.